Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002038 |
The primary purpose of this protocol is to provide fluconazole for the treatment of individual patients who require therapy for serious or life-threatening systemic fungal infection, who have failed on conventional antifungal therapy or have had unacceptable reactions to conventional antifungal therapy, and who are ineligible for other established fluconazole clinical trial protocols.
Condition | Intervention |
---|---|
Candidiasis Mycoses HIV Infections |
Drug: Fluconazole |
Study Type: | Interventional |
Study Design: | Treatment, Dose Comparison |
Official Title: | Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Exclusion Criteria
Co-existing Condition:
A patient will be excluded if he/she has previously had an unacceptable adverse effect due to fluconazole.
A patient will be excluded if he/she has previously had an unacceptable adverse effect due to fluconazole.
AMENDED:
Study ID Numbers: | 012C, 056-152 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002038 |
Health Authority: | United States: Food and Drug Administration |
Mycoses Drugs, Investigational Fluconazole |
Fluconazole Sexually Transmitted Diseases, Viral Candidiasis Clotrimazole Miconazole Acquired Immunodeficiency Syndrome Tioconazole |
Immunologic Deficiency Syndromes Virus Diseases Mycoses HIV Infections Sexually Transmitted Diseases Retroviridae Infections |
Anti-Infective Agents RNA Virus Infections Slow Virus Diseases Immune System Diseases Therapeutic Uses |
Antifungal Agents Lentivirus Infections Infection Pharmacologic Actions |